To develop new whitening agents from natural products, we screened 80 compounds derived from 2 crude drugs in Kampo medicine in a melanin synthesis inhibition assay using murine B16 melanoma cells. 3 The screen revealed that treatment with alisol B, a triterpene from Alismatis rhizoma, significantly 4 decreased both melanin content and cellular tyrosinase activity in B16 cells. However, alisol B did not 5 directly inhibit mushroom tyrosinase activity in vitro. Therefore, we investigated the mechanism 6 underlying the inhibitory effect of alisol B on melanogenesis. Alisol B suppressed mRNA induction of 7 tyrosinase and its transcription factor, microphthalmia-associated transcription factor (MITF). 8
Introduction 1
Melanin is synthesized in the melanosomes of melanocytes, and plays a crucial role in protecting the 2 skin from the harmful effects of ultraviolet radiation. 1) Melanin synthesis or melanogenesis is mainly 3 regulated by 3 melanogenic enzymes: tyrosinase (polyphenol oxidase; EC 1.14.18.10), tyrosinase-related 4 5 plate reader (TECAN Japan). 1 2 Measurement of melanin contents. B16 cells were seeded at a density of 2 x 10 4 cells into 24-well 3 culture plates. After 24 hours, cells were pretreated with 10 μM natural products or DMSO for 30 min 4 and stimulated with 20 μM forskolin and 100 μM IBMX. After 72 hours, cells were washed with ice-cold 5 PBS and lysed with 1 N NaOH at 100 °C for 1 hour. After centrifugation at 16,000 x g for 20 min, the 6 absorbance of the supernatant was measured at 405 nm. Pure Chemical Industries, Japan) or DMSO for 30 min, followed by stimulation with 20 μM 12 forskolin/100 μM IBMX or 0.1 μM α-MSH (GenScript, purity > 95%) for 72 hours. The cells were lysed 13 with 100 mM sodium phosphate buffer (pH 6.8) containing 1% Triton X-100, 10 μg/ml aprotinin, and 10 14 μg/ml leupeptin. After centrifugation at 10,000 x g for 10 min, aliquot (100 μl) of the supernatant was 15 mixed with 100 μl of a substrate solution containing100 mM sodium phosphate buffer (pH 6.8) and 0.5 16 mM L-DOPA, and incubated for 30 min at 37 °C. To monitor the production of dopachrome, the 17 absorbance at 475 nm was measured using the microplate reader. 18
19

Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) and immunoblotting. 20
For RT-qPCR analysis, total RNA extracted from B16 cells was reverse transcribed using ReverTra Ace 21 qPCR RT Master Mix with gDNA Remover (TOYOBO, Japan). Quantitative real-time PCR was 22 conducted using ABI Prism 7000 Sequence Detection System (Applied Biosystems) with Power SYBR 23
Green PCR Master Mix (Applied Biosystems) as previously described.
15) The following specific primers 24 were used: tyrosinase, forward 5'-GTCGTCACCCTGAAAATCCTAACT-3' and reverse 25 5'-CATCGCATAAAACCTGATGGC-3'; MITF, forward 5'-GTATGAACACGCACTCTCGA-3' and 26 reverse 5'-GTAACGTATTTGCCATTTGC-3'; and glyceraldehyde-3-phosphate dehydrogenase 27 (GAPDH), forward 5'-GTGTCCGTCGTGGATCTGA -3' and reverse 5'-28 1
For immunoblotting, cells were lysed with lysis buffer [20 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 2 mM EDTA, 1% Nonidet P-40, 10 μg/ml aprotinin, and 10 μg/ml leupeptin]. After centrifugation at 3 10,000 × g for 10 min, the supernatants were performed for immunoblotting with antibodies against 4 CREB, phospho-CREB, ERK1/2, phospho-ERK1/2, MEK1/2, phospho-MEK1/2 (Cell Signaling 5 Technology), MITF, or β-actin (SantaCruz Biotechnology). 6 7 Statistical analysis. All experiments were performed multiple times to confirm their reproducibility. 8 One representative set of data was shown in the figures. Immunoblot band intensities were quantified 9 using Image J software (NIH). Data were expressed as the mean ± standard error, and statistical analysis 10 was performed by Student's t-test or one-way analysis of variance (ANOVA) with Tukey's multiple 11 comparison test using GraphPad Prism (GraphPad Software). 12 
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Results
14
Identification of melanogenesis inhibitors from a compound library derived from crude drugs in Kampo 15
medicine 16 We first screened 80 chemically defined natural products in traditional Japanese herbal medicines 17 (Kampo medicines) for their ability to inhibit melanin pigmentation in murine B16 melanoma cells. To 18 induce melanin pigmentation, B16 cells were stimulated with a combination of 20 μM forskolin and 100 19 μM IBMX for 72 hours, resulting in a significant increase (> 2-fold) in melanin production (Fig. 1A) . 20 After pretreatment with the compounds at a concentration of 10 μM, cellular melanin contents in 21 forskolin/IBMX-stimulated cells were examined. Among the 80 compounds that we tested, 8 compounds 22
(alisol B, berberine chloride, bergenin, coptisine chloride, corydaline, glabridin, loganin, and nodakenin) 23 apparently decreased melanin pigmentation stimulated with forskolin/IBMX (data not shown). Therefore, 24 we measured melanin contents in B16 cells treated with forskolin/IBMX in the presence and absence of 25 these 8 compounds. As shown in Fig. 1A , treatment with alisol B, berberine chloride, coptisine chloride, 26 corydaline, or glabridin at 10 μM significantly inhibited the increase in melanin production stimulated7 assay. B16 cells were treated with each compound at 10 μM in the presence of forskolin/IBMX for 72 1 hours. As shown in Fig. 1B , berberine chloride, coptisine chloride, and nodakenin had cytotoxic effects 2 on cells, but alisol B and glabridin did not affect cell viability. Because glabridin, a major active 3 flavonoid in G. glabra, has been reported to possess anti-melanogenic activity via the inhibition of 4 tyrosinase, 16) alisol B was chosen as a candidate anti-melanogenic agent (Fig. 1C) . The percent inhibition 5 of melanin production by alisol B at 0.1 μM, 1 μM, and 10 μM was 15%, 69%, and 94%, respectively, 6
and its 50% inhibitory concentration (IC 50 ) was 440 nM (data not shown). This result indicates that alisol 7 B clearly exhibits enough inhibitory activity to reduce melanin production in B16 cells at a concentration 8 of 1 μM. Therefore, for further experiments, alisol B was used at a concentration of 1 μM. 9
10
Effect of alisol B on melanin production and tyrosinase activity in B16 cells 11
Alisol B is one of the major triterpene constituents and is known a bioactive component of A. rhizoma 12 
(dried rhizome of Alisma orientale).
17) Although A. rhizoma is well-known in Chinese traditional 13 medicine and has been used to treat diuresis and hyperlipidemia, 18) no previous study has examined its 14 anti-melanogenic activity. Therefore, we examined whether A. rhizoma reduces melanin synthesis 15 stimulated with forskolin/IBMX. In addition, we tested the effect of A. rhizoma and alisol B on 16 α-MSH-induced melanin pigmentation. B16 cells pretreated with alisol B or A. rhizoma were stimulated 17 with forskolin/IBMX or α-MSH for 72 hours, following which their melanin content was measured. As 18 shown in Fig. 2A Because tyrosinase is the rate-limiting enzyme for melanin synthesis, we next examined the inhibitory 24 effect of alisol B on cellular tyrosinase activity in forskolin/IBMX-or α-MSH-stimulated B16 cells. As 25 shown in Fig. 2C and D, B16 cells showed increased tyrosinase activity upon exposure to 26 forskolin/IBMX and α-MSH. Alisol B significantly suppressed both forskolin/IBMX-and 27 α-MSH-induced cellular tyrosinase activity. Furthermore, we measured the inhibitory effect of alisol B on 28 in vitro mushroom tyrosinase inhibition assay using L-DOPA as a substrate. Alisol B (final concentration 1 at 1 μM and 10 μM) had no inhibitory effect on mushroom tyrosinase activity, although reduced 2 glutathione, a compound that inhibits tyrosinase activity, significantly inhibited (data not shown). These 3 results suggest that the inhibition of melanin synthesis by alisol B is accompanied by a parallel decrease 4 in tyrosinase activity, perhaps by the suppression of tyrosinase expression. 5 6
Effect of alisol B on expression of tyrosinase and MITF 7
We elucidated whether alisol B influences the mRNA expression of tyrosinase. Real-time quantitative 8 PCR analysis revealed that forskolin/IBMX treatment dramatically increased the mRNA level of 9 tyrosinase, and that its induction was significantly inhibited by alisol B (Fig. 3A) . Furthermore, the 10 mRNA expression of MITF, a key transcription factor that regulates the expression of the tyrosinase gene, 11 was also measured. As shown in Fig. 3B , alisol B slightly but significantly reduced the induction of MITF 12 mRNA by forskolin/IBMX. In addition, B16 cells pretreated with alisol B were stimulated with 13 forskolin/IBMX for 30 min or 60 min, and the level of MITF protein in these cells was determined by 14 immunoblot analysis. Fig. 3C shows that MITF protein level was decreased by pretreatment with alisol B. 15 These results indicate that alisol B represses tyrosinase expression partially via the reduction of MITF 16 mRNA and protein levels, leading to the down-regulation of melanin synthesis. 17
18
Effects of alisol B on the signaling pathway involved in melanogenesis 19
MITF expression is induced by CREB activated through phosphorylation at Ser 133 .
19) Thus, we 20
performed immunoblot analysis to determine whether alisol B affects CREB phosphorylation. As shown 21
in Fig. 4A , the phosphorylation of CREB at Ser 133 was hardly detectable in unstimulated B16 cells, but 22 was increased at 30 min and further increased at 60 min after stimulation with forskolin/IBMX. 23 Compared with untreated cells, alisol B remarkably decreased CREB phosphorylation by 61% after 24 stimulation for 60 min, although it had no effect on CREB phosphorylation after 30 min. This indicates 25 that alisol B downregulates MITF expression partially through the inhibition of CREB phosphorylation. 26 In addition to the cAMP/PKA/CREB pathway, the mitogen-activated protein kinase (MAPK) signaling 27 pathway is also involved in melanogenesis. 7, 8, 20) The activation of ERK MAPK leads to MITF 28 ubiquitination and degradation, and thus inhibits melanin synthesis.
9, 21) Therefore, we investigated 1 whether alisol B influences ERK activation. After forskolin/IBMX stimulation, ERK1/2 was transiently 2 phosphorylated with a peak at 30 min, and then diminished (Fig. 4B) . Pretreatment with alisol B induced 3 prolonged phosphorylation of ERK1/2, which remained strongly phosphorylated after 60 min. Similarly, 4 the phosphorylation of MEK1/2, an upstream kinase of ERK, was also sustained by alisol B treatment 5 (Fig. 4C) . Finally, we examined whether the inhibition of the MEK/ERK pathway affects MITF reduction 6 by Alisol B. B16 cells were treated with Alisol B in the presence or absence of a MEK-specific inhibitor 7 U0126, followed by stimulation with forskolin/IBMX for 30 min. As shown in Fig. 4D , MITF protein 8 level was significantly reduced by alisol B and the reduction was slightly recovered by U0126. These 9 results indicate that alisol B plays a dual role, namely the inhibition of the cAMP/PKA/CREB pathway 10 and activation of the MEK/ERK pathway, thereby inducing the downregulation of MITF. 11 12 Discussion 13 The development of natural products from various plant sources that inhibit melanin formation and 14 tyrosinase activity has been actively pursued, because the existing skin-whitening products have been 15 reported to exhibit some side effects. To develop safer and more efficient pharmaceutical and cosmetic 16 products, we focused on chemically defined natural products in Kampo medicines, which are traditional 17 Japanese herbal medicines. In the present study, we identified alisol B 18
[(23S,24R)-24,25-epoxy-11b,23-dihydroxy-8a,9b,14b-dammar-13(17)-en-3-one] as an anti-melanogenic 19 compound, whose activity is higher than that of a known tyrosinase inhibitor, glabridin. Alisol B is one of 20 the major active constituents of A. rhizoma, which also contains alisol A, C, and their related compounds 21 as active triterpenoids.
17) Although A. rhizoma has been used because of its diuretic, hypolipidemic, and 22
anti-inflammatory properties, 18) its anti-melanogenic activity has not been studied. We found that A. 23 rhizoma has little anti-melanogenic activity. Furthermore, alisol A 24
[(23S,24R)-11b,23,24,25-tetrahydroxydammar-13(17)-en-3-one], which was also tested in this study, had 25 a much lower inhibitory effect than alisol B (27%-55% alisol A vs. 64%-75% alisol B inhibitory activity 26 at 10 μM) (data not shown). A previous study revealed that alisol B induces autophagy via the inhibition 27 of the sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase pump, whereas alisol A exhibits a much lower 28 inhibitory effect. 22) These results suggest that a slight structural difference between alisol A and B may 1 exert a distinct influence on the physiological function. 2
Although alisol B significantly inhibited cellular tyrosinase activity stimulated with forskolin/IBMX 3 and α-MSH, it (even at 10 μM) did not affect tyrosinase activity in an in vitro system using mushroom 4 tyrosinase. Because tyrosinase is the rate-limiting enzyme in the melanogenic process, most of the 5 strategies for the development of skin-whitening agents are based on the inhibition of tyrosinase activity. 6 In fact, tyrosinase inhibitors, such as kojic acid and arbutin, are used in cosmetic products and as 7 depigmenting agents for hyperpigmentation. On the other hand, the suppression of tyrosinase gene 8 expression is also a target for the development of skin-whitening products. A recent report has 9 demonstrated that hispolon, a compound of Phellinus linteus, inhibits melanogenesis through the 10 down-regulation of tyrosinase and MITF expression.
23) The inhibitory effect of alisol B on melanogenesis 11 also seems to be attributed to the suppression of tyrosinase gene expression rather than to the direct 12 inhibition of tyrosinase activity. 13 The promoters of tyrosinase, TRP-1, and TRP-2 possess the consensus binding site for MITF, which is 14 a master regulator of melanocyte development, and their expression is activated by MITF. Although alisol 15 subsequent reduction of tyrosinase. In addition, alisol B had no effect on the activation of raf-1, which is 1 an upstream positive modulator of the MEK/ERK pathway (data not shown), suggesting that raf-1 is not a 2 target for alisol B. These results show that alisol B probably diminishes melanogenesis via two signaling 3 pathways: the PKA-CREB-MITF pathway and the MEK-ERK-MITF pathway. 4
In conclusion, we revealed that alisol B decreases MITF level through the regulation of the CREB and 5 ERK pathways in B16 melanoma cells, leading to the inhibition of tyrosinase expression, and 6 subsequently melanin production. These findings strongly suggest that alisol B can become a useful 7 therapeutic agent for the treatment of hyperpigmentation, and can be used as an ingredient in whitening 8 and lightening cosmetics. However, further research is required to evaluate the efficacy and safety of 9 alisol B. 
